Behcet's Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
SKU ID : TNV-14620395 | Publishing Date : 28-Aug-2019 | No. of pages : 150
Detailed TOC of Behcet's Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Small molecules - Market size and forecast 2018-2023
• Biologics - Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Amgen Inc.
• Celgene Corp.
• Eisai Co. Ltd.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Drug designations
Exhibit 43: Side effects of small molecule-based drugs used for treatment of Behcet’s disease
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AbbVie Inc. - Vendor overview
Exhibit 51: AbbVie Inc. - Business segments
Exhibit 52: AbbVie Inc. - Organizational developments
Exhibit 53: AbbVie Inc. - Geographic focus
Exhibit 54: AbbVie Inc. - Key offerings
Exhibit 55: AbbVie Inc. - Key customers
Exhibit 56: Amgen Inc. - Vendor overview
Exhibit 57: Amgen Inc. - Product segments
Exhibit 58: Amgen Inc. - Organizational developments
Exhibit 59: Amgen Inc. - Geographic focus
Exhibit 60: Amgen Inc. - Key offerings
Exhibit 61: Amgen Inc. - Key customers
Exhibit 62: Celgene Corp. - Vendor overview
Exhibit 63: Celgene Corp. - Business segments
Exhibit 64: Celgene Corp. - Organizational developments
Exhibit 65: Celgene Corp. - Geographic focus
Exhibit 66: Celgene Corp. - Key offerings
Exhibit 67: Celgene Corp. - Key customers
Exhibit 68: Eisai Co. Ltd. - Vendor overview
Exhibit 69: Eisai Co. Ltd. - Business segments
Exhibit 70: Eisai Co. Ltd. - Organizational developments
Exhibit 71: Eisai Co. Ltd. - Geographic focus
Exhibit 72: Eisai Co. Ltd. - Segment focus
Exhibit 73: Eisai Co. Ltd. - Key offerings
Exhibit 74: Eisai Co. Ltd. - Key customers
Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 82: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 83: Johnson & Johnson Services, Inc. - Business segments
Exhibit 84: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 85: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 86: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 87: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 88: Johnson & Johnson Services, Inc. - Key customers
Exhibit 89: Mylan NV - Vendor overview
Exhibit 90: Mylan NV - Product segments
Exhibit 91: Mylan NV - Organizational developments
Exhibit 92: Mylan NV - Geographic focus
Exhibit 93: Mylan NV - Segment focus
Exhibit 94: Mylan NV - Key offerings
Exhibit 95: Mylan NV - Key customers
Exhibit 96: Novartis AG - Vendor overview
Exhibit 97: Novartis AG - Business segments
Exhibit 98: Novartis AG - Organizational developments
Exhibit 99: Novartis AG - Geographic focus
Exhibit 100: Novartis AG - Segment focus
Exhibit 101: Novartis AG - Key offerings
Exhibit 102: Novartis AG - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors